Would you recommend that oncologists include acute cardiovascular events in informed consent for checkpoint inhibitor treatment?

Given accumulating retrospective evidence of these events, how would you suggest oncologist discuss this with their patients prior to starting? (note – this is due to several papers including this: Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy | Blood | American Society of Hematology (ashpublications.org) and this: Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque | Circulation (ahajournals.org))